Benjamin Parcher serves as the Digital Product Access Lead for Mental Health at Boehringer Ingelheim, where he leverages over 20 years of extensive experience in the biopharmaceutical and digital therapeutics sectors. His role is pivotal in shaping the strategic direction of digital health investments, ensuring...
Benjamin Parcher serves as the Digital Product Access Lead for Mental Health at Boehringer Ingelheim, where he leverages over 20 years of extensive experience in the biopharmaceutical and digital therapeutics sectors. His role is pivotal in shaping the strategic direction of digital health investments, ensuring that they align with both current market needs and future opportunities. By collaborating with key stakeholders, Benjamin defines comprehensive technology investment plans and roadmaps that are essential for driving alignment across various functions, including engineering, medical, and commercial teams.
At Boehringer Ingelheim, Benjamin has successfully led and executed hundreds of Market Access and Health Economics and Outcomes Research (HEOR) projects, contributing to the evidence generation and reimbursement strategies for 45 product launches in the U.S. His expertise in design strategy and healthcare information technology enables him to navigate the complexities of medication therapy management and clinical research, ensuring that innovative solutions are effectively integrated into the healthcare ecosystem.
Benjamin’s leadership is characterized by his ability to influence cross-functional teams, fostering collaboration that enhances the development of digital therapeutics aimed at improving mental health outcomes. His adeptness in project management and data analysis allows him to evaluate the impact of digital products on patient access and overall healthcare delivery. As a recognized leader in the field, Benjamin is committed to advancing the role of digital health solutions in transforming mental health care, ultimately driving better patient outcomes and enhancing the value of biopharmaceutical investments.
